Lubricant Industry ESG Thematic Report, 2022 | Grand View Research, Inc. [Business]
The
average ESG disclosure score for the lubricant market is between 55% and 65%.
Our proprietary Environment, Social, and Corporate Governance (ESG) scoring
framework analyzed 65 parameters across ESG, as represented in
the methodology section of this document. Royal Dutch Shell, British
Petroleum (BP), Chevron, and 11 more market leaders were part of our research.
Three out of five companies we researched scored above the average industry
score. However, four market leaders need to focus more on ESG reporting and
transparency as they scored well below 50%.
For More Details: https://astra.grandviewresearch.com/lubricant-industry-esg-outlook
Environmental insights
Lubricant
comprises less than 10% additives and 90% base oil (like petroleum fractions,
called mineral oils). In rotating machinery, lubrication is crucial for
efficiency and durability. Lubrication reduces friction between machine parts
and enables them to move smoothly in a given direction. There is a negative
impact of lubricant on the environment, as it causes serious contamination of
soils and groundwater, as well as accumulates in plants and animal tissues.
There are various measures or technologies used by companies globally for the
sustainability of lubricants. One of the main alternatives to petroleum-based
lubricants is bio-based lubricants, which can help reduce environmental impact
and create green companies.
Social insights
Broadly,
social metrics represent an assessment of risks that a company might experience
from human capital and community, both. The parameters that are considered in
this category include not only the employee turnover rate but also health &
safety parameters, including injury rates, OHSAS certifications, employee
engagement programs, training, and community development, among others. Among
the companies within the sector, Idemitsu Kosan ranks highest on the social
pillar, with a score of around 70%. The company has institutionalized robust
human rights monitoring mechanisms not only within its own operations but also
across the operations of its entire supply chain.
Governance insights
The
governance aspect within the purview of ESG assessment is one of the most
important foundation stones of a company, which includes various metrics,
including business ethics, board structure, financial transparency,
anti-corruption, and insider trading, among others. As per Grand View
Research’s ESG scoring model, Chevron ranks the highest in corporate governance
among its peers operating within the lubricants sector. The company has the
highest number of independent directors (over 90% of the board comprises
independent directors), which enhances corporate credibility and governance
standards in the eyes of investors and consumers. Chevron has also
institutionalized one of the best-in-class ethics platforms that manage any
form of misconduct within the company.
Request for Free Demo: https://astra.grandviewresearch.com/lubricant-industry-esg-outlook/request/rs1
Electric Passenger Cars Industry ESG Thematic Report, 2022 | Grand View Research, Inc. [Business]
The average ESG disclosure score for the electric passenger cars industry is between 60% and 70%. Our proprietary ESG scoring framework analyzed 65 parameters across the environment, social, and corporate governance, as represented in the methodology section of this document. General Motors (GM), Mitsubishi Motor Corporation (MMC), and seven other market leaders were part of our research. Seven out of nine companies we researched scored above the average industry score. However, two market leaders need to focus more on ESG reporting and transparency as they scored well below 50%.
For More Details: https://astra.grandviewresearch.com/electric-passenger-cars-industry-esg-outlook
Environmental insights
In recent years, Electric Vehicles (EVs) have become more popular, which has been good news for the environment. Switching to EVs helps in avoiding the exhaustion of finite resources and also provides another way to reduce carbon footprint because these vehicles have no tailpipe emissions, which is a direct contributor to global warming. Companies in the EV market have institutionalized stringent targets to fight climate change and global warming. Most of the players like Nissan motors have programs for managing waste and reducing water consumption through the 3R (Reduce, Reuse, Recycle) and Circular Economy models.
Social insights
Social metrics assess the risk to a company from community and human capital, which include employees & stakeholders and their relationship with them. Employees’ and safety parameters covering OHSAS certifications, and injury rates, alongside employee training & development, employee engagement programs, privacy, supply chain transparency, and human rights are majorly included in this category. With a social disclosure score of 67%, Toyota Motor Corporation ranks the highest. Most of the companies, including the top three, have separate supplier CSR guidelines or human rights policies aligned with the United Nations Guiding Principles on Business and Human rights, except Volkswagen AG, which lacks a separate supplier code of conduct on human rights or any such supply chain policy.
Governance insights
Corporate governance practices are core to an organization as understanding opportunities and risks in governance is critical for decision-making. Governance is one of ESG’s core components and assesses the purpose of a corporation, the role of directors, the make-up of directors, gender diversity, equity, and compensation of boards. Independent directors on the board play a crucial role in improving governance standards and corporate credibility. In 2020, GM had the highest representation of independent directors on board with over 90% independent directors on its board. Furthermore, in terms of diversity in the board, GM had the highest percentage of females on board, with more than 50% female members on board.
Request for Free Demo: https://astra.grandviewresearch.com/electric-passenger-cars-industry-esg-outlook/request/rs1
Point-Of-Sale (POS) Terminal Industry ESG Thematic Report, 2022 | Grand View Research, Inc. [Business]
The average ESG disclosure score for the point-of-sale terminal Industry is between 60% and 70%. Our proprietary Environment, Social, and Corporate Governance (ESG) scoring framework analyzed 65 parameters across ESG, as represented in the methodology section of this document. Hewlett Packard Inc., Toshiba Corporation, Panasonic Corporation, and seven more market leaders were part of our research. Six out of 10 companies we researched scored above the average industry score. However, three market leaders need to focus more on ESG reporting and transparency, as they scored well below 50%. Our research shows that most of the sustainability-related revelations have been made around ecological measurements, which stand at almost 75%, followed by governance and social with a score of ∼ 60% and ∼ 50%, respectively. Hewlett-Packard, Inc.
%20Terminal%20Industry%20ESG.png "Point-Of-Sale (POS) Terminal Industry ESG")
For More Details: https://astra.grandviewresearch.com/point-of-sale-terminal-industry-esg-outlook
Environmental insights
During the COVID-19 pandemic, the global transition from the coin- and paper-based payments to digital transactions implies that the quantity of Point-of-Sale (POS) terminals is rapidly growing. However, this development is accompanied by liability; not exclusively to consider the effect the increased number of gadgets has on various factors like financial incorporation, additionally with the ecological impact of the assembling process of payment terminals, their transportation, use, support, and end-of-life handling. Some of the significant sustainability challenges faced by the industry are generation & disposal of e-waste during the end-of-life of POS equipment; large-scale use of paper in the form of printed receipts, resulting in waste generation; and the supply chain disruptions arising from semiconductor shortages, which have led to the adoption of various methods such as reducing top margin, on-demand printing, receipt compression, and greener manufacturing, such as halogen-free cases & recyclable packaging.
Social insights
Predominantly, social metrics consist of an assessment that covers both the parameters–human capital and community. The variables that are accounted for in this classification are employee turnover rate as well as their wellbeing & security, including injury rates, and OHSAS certificates, alongside government assistance provided to both workers & clients. Among the companies within the sector, Toshiba Corporation ranks highest on the social pillars with a score of around 90%. It has standardized robust human rights checking components not only within its own operations but also across the supply chain. It also considers the health and safety of its employees as a priority factor.
Governance insights
The Governance aspect within ESG evaluation is one of the principal foundation stones of an association, which integrates various estimations, including business ethics, board structure, monetary issues, payoff, succession planning, and statutory audits, among others. As per Grand View Research’s ESG scoring model, HP ranks the highest in corporate governance among its peers operating in the point-of-sale terminal market. The organization has the highest number of independent directors (more than 91% of the board includes autonomous chiefs or independent directors), which enhances corporate responsibility and administrative principles in accordance with investors and consumers.
Request for Free Demo: https://astra.grandviewresearch.com/point-of-sale-terminal-industry-esg-outlook/request/rs1
Antiviral Drugs Market Survey, Opportunities and Trends to 2028 [Business]
Antiviral Drugs Industry Overview
The global antiviral drugs market size to be valued at USD 60.0 billion by 2028 and is expected to grow at a compound annual growth rate (CAGR) of (-0.6%) during the forecast period. The introduction of the generic version of antiviral medicines and growing awareness about the availability of various vaccines for viral infections is affecting the growth during the forecast period.
However, the increasing prevalence of viral infections such as HIV, Herpes, Influenza, and others are expected to increase the demand for antiviral medicines over the forecast period. For instance, according to UNAIDS, in 2020, more than 37 million individuals were living with HIV across the globe. Out of these, approximately 1.5 million new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has significantly increased market growth in 2020 whereas, a negative impact of the pandemic has been observed for other applications of antiviral drugs.
The increasing incidence of viral infection across the globe is a major factor driving the demand for antiviral drugs over the forecast period. According to WHO, globally, an estimated 325 million people are living with hepatitis infection and out of these, around 71 million have chronic hepatitis C virus infection. Moreover, the U.S. Department of Health and Human Services has estimated that 2.4 million people are living with hepatitis C in the United States and around 850,000 individuals in the country have hepatitis B infection. An increasing base of patients is anticipated to increase the demand for antiviral drugs globally.
Gather more insights about the market drivers, restrains and growth of the Global Antiviral Drugs Market
Increasing approval and expected commercialization of novel medicines for viral infections are anticipated to drive market growth. For instance, in November 2020, the U.S. FDA has approved a supplemental New Drug Application for Roche’s Xofluza for the treatment of influenza in patients 12 years of age and older. Moreover, the major players in the market have launched many novel medicines in 2 to 3 years for the treatment of viral infections. For instance, Gilead Sciences, Inc. has launched Biktarvy, Symtuza, and Veklury for the treatment of viral infections. Furthermore, GlaxoSmithKline plc. has launched Dovato, Cabenuva, and Juluca for the treatment of diseases caused by the virus. An increase in the introduction of novel products in the market will drive growth over the next 2 to 3 years.
The outbreak of the COVID-19 pandemic has significantly increased the demand for antiviral medicines globally. The treatment of novel coronavirus has increased the demand for broad-spectrum antiviral drugs to manage the disease. Remdesivir, favipiravir, oseltamivir, and other combination medicines are highly prescribed for the treatment of COVID-19. Moreover, governments are increasing funding to pharmaceutical companies to develop novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government has announced an investment of more than USD 3 billion to fasten the discovery, development, and manufacturing of antiviral medicines for COVID-19 treatment. The rising incidence of disease coupled with increasing R&D will increase the demand for antiviral drugs in the next 2 to 3 years.
Increasing collaborations for the development and manufacturing of antiviral drugs are expected to result in the development of a high number of novel drugs in the coming years. The key players in the market are collaborating for the R&D of new therapies to reduce the burden of viral infection treatment. For instance, in 2020, Gilead Sciences, Inc. has signed licensing agreement with pharmaceutical manufacturers such as Cipla Ltd., Hetero Labs Ltd., Dr. Reddy's Laboratories Ltd., Mylan, and others to expand the supply of remdesivir.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
• Immunotherapy Drugs Market: The global immunotherapy drugs market size was valued at USD 110.55 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.92% from 2022 to 2030. The market is primarily driven by the rising incidence of chronic diseases globally.
• Topical Drugs Market: The global topical drugs market size was valued at USD 97.42 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.1% from 2022 to 2030. The industry growth is primarily driven by the rising incidence of skin disorders and diabetes. According to the British Journal of Dermatology, skin diseases affect almost one-third of the global population.
Antiviral Drugs Market Segmentation
Grand View Research has segmented the global antiviral drugs market on the basis of drug class, type, application, and region:
Antiviral Drug Class Outlook (Revenue, USD Million, 2017 - 2028)
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others
Antiviral Drugs Type Outlook (Revenue, USD Million, 2017 - 2028)
• Branded
• Generics
Antiviral Drugs Application Outlook (Revenue, USD Million, 2017 - 2028)
• HIV
• Hepatitis
• Herpes
• Influenza
• Others
Antiviral Drugs Regional Outlook (Revenue, USD Million, 2017 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Key Companies profiled:
Some prominent players in the Global Antiviral Drugs Market include
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• AbbVie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.
Order a free sample PDF of the Antiviral Drugs Market Intelligence Study, published by Grand View Research.
Augmented Reality & Virtual Reality In Healthcare Market Growth Analysis And Forecast to 2028 [Business]
Augmented Reality & Virtual Reality In Healthcare Industry Overview
The global Augmented Reality & Virtual Reality in healthcare market size was valued at USD 2.0 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 27.2% from 2021 to 2028.
Technological advancements and digitalization in healthcare, favorable government initiatives, rising healthcare expenditure, growing usage in surgical procedures, and medical training are some of the fundamental factors anticipated to boost the growth and adoption of the augmented reality (AR) and virtual reality (VR) technologies in the healthcare industry. These technologies have wide applications in healthcare including surgeries, diagnostics, rehabilitation, training, and education.
Augmented and virtual reality techniques are being increasingly adopted in surgeries and diagnostics. Systems such as touch surgery use virtual reality to provide a view of the patient’s anatomy and physiology, thereby providing opportunities for surgeons in the operating room, This, in turn, is expected to augment the growth of the market for augmented reality and virtual reality in healthcare. The growing adoption of Augmented Reality (AR) and Virtual Reality (VR) technologies in medical surgeries to optimize surgical procedures and increase the efficiency of treatment is one of the key factors driving market growth over the past few years. For instance, in December 2019, Augmedics launched the Xvision Spine AR guidance system for spine surgeries in the U.S. This solution allows the surgeon to view the 3D spinal anatomy of the patient during the surgery. Augmedics also received the U.S. FDA approval for Xvision in December 2019. Moreover, the increasing practice of storing medical images and patient data on the AR/VR platform helps in reducing requirements for expensive screens and unnecessary staff.
Gather more insights about the market drivers, restrains and growth of the Global Augmented Reality & Virtual Reality In Healthcare Market
Additionally, AR is being widely adopted for education and training purposes for medical personnel. Since AR-based learning modules provide anatomical visualization and simulation it gives the medical personnel a more wholesome complete learning experience. Moreover, these learning modules are even being used to train patients and help them understand the treatment flow and care management better. AR-based image visualization assists the surgeons and enhancing their accuracy and precision during complex surgeries. For instance, in February 2019 Philips Healthcare collaborated with Azurion and Microsoft to develop a mixed reality concept to provide a 3D holographic AR environment derived from multiple image modalities to assist surgeons.
During the outbreak of the COVID-19 pandemic, AR & VR in healthcare was influenced positively owing to the technological advancements in this space. For instance, in April 2020 XRHealth extended its application by raising USD 7 million to expand its telehealth platform. Similarly, Imperial College and St. Mary’s Hospital in London are using augmented reality glasses to visualize 3D imaging of blood vessels during reconstructive surgeries. Augmented reality and virtual reality in healthcare help in efficiently managing the treatment schedules, treatment delivery, and plans, and thereby it is anticipated to exponentially grow during the pandemic. Additionally, the decreasing costs in healthcare, rapid digitalization of healthcare, and improved delivery of effective health services are expected to drive growth. AR and VR in healthcare are gaining momentum due to widespread adoption in telemedicine, medical training & education, patient care management, medical marketing during the COVID-19 pandemic.
Furthermore, mergers and acquisitions, product development and launches, partnerships, and collaborative agreements are some of the crucial initiatives being undertaken by key players, which are expected to propel market growth. For instance, in January 2021 Hologic Inc acquired Biotheranostics, a molecular diagnostics company for USD 230 million. Through this acquisition, Hologic Inc and Biotheranostics will combine their capabilities and utilize their expertise in oncology diagnostics and advanced woman health diagnostics.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
• Oncology Information Systems Market: The global oncology information systems market was valued at USD 2.4 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030. Monumental growth of healthcare IT, the increasing global prevalence of cancer, increasing expenditure in development around treatment & solutions for cancer care, and increasing adoption of OIS solutions by healthcare facilities is some of the key factors anticipated to drive the growth of the market.
• Real World Evidence Solutions Market: The global real world evidence solutions market size was valued at USD 39.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.1% from 2022 to 2030. Support from regulatory bodies for using real world evidence (RWE) solutions and an increase in R&D spending are anticipated to boost the market growth.
Augmented Reality & Virtual Reality In Healthcare Market Segmentation
Grand View Research has segmented the global augmented reality & virtual reality in healthcare market on the basis of component, technology, and region:
AR & VR In Healthcare Component Outlook (Revenue, USD Million, 2016 - 2028)
• Hardware
• Software
• Service
AR & VR In Healthcare Technology Outlook (Revenue, USD Million, 2016 - 2028)
• Augmented Reality
• Virtual Reality
AR & VR In Healthcare Regional Outlook (Revenue, USD Million, 2016 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Key Companies profiled:
Some prominent players in the Global Augmented Reality & Virtual Reality In Healthcare Market include
• CAE
• GE Healthcare
• Koninklijke Philips N.V.
• Intuitive Surgical
• Siemens Ltd
• Eon Reality, Inc
• Layar
• Bioflight VR
• WorldViz
• TheraSim Inc
• Mindmaze
Order a free sample PDF of the Augmented Reality & Virtual Reality In Healthcare Market Intelligence Study, published by Grand View Research.
Hospital Information System Market Survey, Opportunities and Trends to 2028 [Business]
Hospital Information System Industry Overview
The global hospital information system market size was valued at USD 57.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2021 to 2028.
Rising government initiatives and increasing demand from hospitals to deploy advanced IT solutions for effective operational efficiency are some of the key factors for the increase in the adoption of hospital information systems (HIS). The increasing need to reduce healthcare expenditure due to hospital workflow inefficiencies is expected to increase hospital information systems implementation worldwide. Thus, the growing demand for reduced healthcare costs and effective clinical outcomes is one of the key factors responsible for the adoption of information systems in developed economies and also in emerging economies, such as India, China, the Philippines, and Brazil.
Developing and developed regions are struggling to achieve high care delivery standards, which are both cost-effective and quality-oriented with minimum medical errors. With the help of HIS, providers are now able to streamline their workflows by offering enhanced patient outcomes about costs through investigational mining of electronic patient records for identifying inherent medical inaccuracies in the system. It enables them to offer cost-effective services to patients while reducing resources wastage. Moreover, increasing penetration of technologically advanced hospital management solutions is also aiding the market growth.
Gather more insights about the market drivers, restrains and growth of the Global Hospital Information System Market
The increased implementation of healthcare IT solutions and services by hospitals to provide enhanced patient care at reduced expenses, coupled with the growing need to upgrade already existing information systems, is likely to be a key driving factor. Moreover, consistent upgrades in healthcare and IT infrastructures along with increased adoption of cloud computing in hospital settings are also contributing significantly to the market growth. Since, healthcare data is subject to stringent regulatory oversight to ensure patient confidentiality, safe and secure storage, user-level authorization, traceability of information, and mitigation of other cybersecurity threats. Thus, hospitals are switching from on-premises deployments to cloud-based information systems to maintain high data security and avoid security breaches.
In addition, the growing adoption of EHR systems among developing economies owing to increased utilization of electronic health records for patient-centric care is expected to significantly boost the market growth over the next few years. EHR emerged as one of the key potential segments in hospital information systems, primarily owing to the rising demand for streamlining electronic healthcare solutions, technological advancements in healthcare information IT, and growing demand for EHR-integrated tools. Also, government initiatives promoting EHR are likely to propel the demand for electronic systems. EHRs offer a range of advantages to hospitals and patients, ultimately leading to increased system productivity and patient satisfaction.
Furthermore, associated benefits with these information systems, such as operational cost-reduction minimized errors in the end-use facility, and increased successful operational outcomes, are expected to propel market growth. Moreover, government initiatives supporting eHealth programs in developed as well as developing regions and incentives promoting information systems implementation in hospital settings in certain countries are further expected to drive the market over the forecast period.
Browse through Grand View Research's Healthcare IT Industry Research Reports.
• 5G In Healthcare Market: The global 5G in healthcare market size was valued at USD 34.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 34.5% from 2022 to 2030. The global market is driven by the rising adoption of robotic surgery and telehealth.
• Women’s Health App Market: The global women’s health app market size was valued at USD 2.7 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 19.45% from 2022 to 2030. The increasing incidence of diseases among women and the high penetration of smartphones is expected to drive the market growth.
Hospital Information System Market Segmentation
Grand View Research, Inc. has segmented the global hospital information system market report on the basis of type, deployment, component, and region:
Hospital Information System Type Outlook (Revenue, USD Million, 2016 - 2028)
• Electronic health record
• Electronic medical record
• Real-time healthcare
• Patient engagement solution
• Population health management
Hospital Information System Deployment Outlook (Revenue, USD Million, 2016 - 2028)
• Web-based
• On-premises
• Cloud-based
Hospital Information System Component Outlook (Revenue, USD Million, 2016 - 2028)
• Software
• Hardware
• Services
Hospital Information System Regional Outlook (Revenue, USD Million, 2016 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• MEA
Key Companies profiled:
Some prominent players in the Global Hospital Information System Market include
• Carestream Health
• Siemens Healthineers
• McKesson Corporation
• Philips Healthcare
• Merge Healthcare Inc. (IBM)
• GE Healthcare
• Cerner Corporation
• Allscripts
• NextGen Healthcare
Order a free sample PDF of the Hospital Information System Market Intelligence Study, published by Grand View Research.
microRNA Market Overview, Top Key Players, Growth Analysis And Forecast to 2028 [Business]
microRNA Market
microRNA Industry Overview
The global microRNA market size was valued at USD 854.6 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 19.8% from 2021 to 2028.
Key trends that have collectively contributed to market growth over the years include emerging microRNA (miRNA) tools for disease-associated analytical applications, immense traction gained by miRNA target prediction and identification, and persisting wide adoption of the majority of the miRNA tools. Additionally, miRNAs are amongst the most important potential biopharmaceutical candidates that are entering in commercial space for developing potential future medicines.
Biopharmaceutical companies are increasingly engaging in the search for new therapeutic molecules that can act as new drugs which is further driving the market for microRNA. There are several miRNA-based candidates that are under clinical trials such as anti-miR compounds and specific inhibitors for miRNAs which can act as potential therapeutic solutions. Hence, RNA therapeutics is considered a trending investing area that will lead to the development of profitable drugs.
Gather more insights about the market drivers, restrains and growth of the Global microRNA Market
Increasing adoption of microRNA as a biomarker is driving the market. The miRNA biomarkers are of particular focus on genome-wide studies, and data-driven methodology, as they demonstrate high reproducibility and robustness when compared to traditional methods. Hence, they serve as promising candidates for the development of biomarkers. Moreover, the growing interest in liquid biopsies has further led to the increasing importance of miRNAs for biomarker discovery and development.
A steep increase in the research activities exploring the potential of miRNA biomarkers across prognosis, diagnosis, and therapeutics is expected to favor the market expansion in the near future. For instance, in January 2020, researchers explored the possibility of miRNA found in peripheral blood as a biomarker for diagnosing Bipolar II disorder (BD-II) using next-generation sequencing. miRNAs can be a possible noninvasive solution for the diagnosis of other neurodegenerative disorders.
In addition, the technological innovation for improving the sensitivity and selectivity of miRNA detection is further contributing to the growth of the market for microRNA. The newly developed methods for miRNA detection include nanoparticle-based amplification, RCA-based methods, DSN-based methods, LAMP-based methods, and enzyme-free amplification. Similarly, in January 2020, researchers developed a program-based isothermal amplification technique for specific and quantitative digital measurement of miRNA. The advantage of the system is that contamination is reduced by the fact that this system is dependent on the signal amplification process rather than direct replication of the targeted sequence, as it is done using PCR-based approaches.
Browse through Grand View Research's Biotechnology Industry Research Reports.
• Genotyping Market: The global genotyping market was valued at USD 12.65 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 15.6% from 2022 to 2030. The growth can be attributed to technological advancements, the rising prevalence of cancer & genetic disorders, and increasing R&D funding for precision medicine research.
• Cell Culture Media Market: The global cell culture media market size was valued at USD 3,616.8 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals.
microRNA Market Segmentation
Grand View Research has segmented the global microRNA market on the basis of products, services, application, end-use, and region:
microRNA Products Outlook (Revenue, USD Million, 2017 - 2028)
• Instruments
• Consumables
microRNA Services Outlook (Revenue, USD Million, 2017 - 2028)
• Service Type
• By Specimen
microRNA Application Outlook (Revenue, USD Million, 2017 - 2028)
• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others
microRNA End-use Outlook (Revenue, USD Million, 2017 - 2028)
• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other end-users
microRNA Regional Outlook (Revenue, USD Million, 2017 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Key Companies profiled:
Some prominent players in the Global microRNA Market include
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• Synlogic
• QIAGEN
• GeneCopoeia, Inc.
• New England Biolabs
• Quantabio
• NanoString
• BioGenex
• SeqMatic LLC
• Miltenyi Biotec
• Sistemic Scotland Limited
• Biodynamics Laboratory Inc.
• OriGene Technologies, Inc.
Order a free sample PDF of the microRNA Market Intelligence Study, published by Grand View Research.
Pneumatic Nebulizers Market Survey, Opportunities and Trends to 2028 [Business]
Pneumatic Nebulizers Market
Pneumatic Nebulizers Industry Overview
The global pneumatic nebulizers market size was valued at USD 644.34 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.0% over the forecast period.
The increasing incidence of chronic respiratory diseases, demand for home healthcare devices, and growing geriatric population are the factors expected to drive the market. According to statistics published by the CDC, approximately 18.4 million adults in the U.S. suffer from asthma. The COVID-19 pandemic has impacted all industries, including the pneumatic nebulizers market. Asthma or COPD patients, who were aware of the risk of airborne transmission of COVID-19, were hesitant about the use of inhaled medications, which are considered as a potential source of viral transmission and immunosuppression.
Gather more insights about the market drivers, restrains and growth of the Global Pneumatic Nebulizers Market
However, medical practitioners advised all such patients to continue using their prescribed inhaled medications, including nebulizers. Therefore, the overall impact of COVID-19 on the market was minimal. Easy availability of compact pneumatic nebulizers ideal for home use, and technological innovations in these devices to reduce the sound created by them & improve their functionality, are increasing their adoption in-home healthcare. Moreover, these devices are favored by third-party payers, such as insurance companies, as they aim to reduce costs while providing quality healthcare services. These factors are expected to boost the adoption over the forecast period.
Browse through Grand View Research's Medical Devices Industry Research Reports.
• Corneal Implants Market: The global corneal implants market size was valued at USD 392.9 million in 2021 and is anticipated to register a compound annual growth rate (CAGR) of 6.5% from 2022 to 2030. The increasing prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry's growth.
• Wearable Injectors Market: The global wearable injectors market size was valued at USD 6.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 15.29% from 2022 to 2030. The main market-driving factors are the prevalence of chronic illnesses, rising geriatric population, and growing concern over needle stick injuries.
Pneumatic Nebulizers Market Segmentation
Grand View Research has segmented the global pneumatic nebulizers market on the basis of the product, end-use, and region:
Pneumatic Nebulizers Product Outlook (Revenue, USD Million, 2016 - 2028)
• Breath-actuated
• Vented
Pneumatic Nebulizers End-use Outlook (Revenue, USD Million, 2016 - 2028)
• Hospitals & Clinics
• Home Healthcare
Pneumatic Nebulizers Regional Outlook (Revenue, USD Million, 2016 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
Key Companies profiled:
Some prominent players in the Global Pneumatic Nebulizers Market include
• Koninklijke Philips N.V.
• Omron Corp.
• PARI Pharma
• General Electric Company
• Allied Healthcare Products, Inc.
• BD (Becton, Dickinson & Company)
• GF Health Products, Inc.
• Medline Industries, Inc.
• Briggs Healthcare
• Vectura Group Plc
Order a free sample PDF of the Pneumatic Nebulizers Market Intelligence Study, published by Grand View Research.
Next-Generation Sequencing Data Analysis Market Future Landscape To Witness Significant Growth to 2028 [Business]
Next-Generation Sequencing Data Analysis Industry Overview
The global next-generation sequencing data analysis market size was valued at USD 561.6 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.02% from 2021 to 2028.
Next-generation sequencing (NGS) has effectively helped in studying epigenomic as well as genomic patterns associated with various biological processes. However, issues pertaining to storage, management, and accessing information are expected to provide the market with potential R&D opportunities, consequently fueling the growth of the market. Research communities that use high-throughput sequencers demand Laboratory Information Management Systems (LIMSs) for handling and archiving sequencing information. Cloud-based platforms offer favourable solutions for computationally intensive tasks during the analysis of NGS data. Therefore, it has become a quick and easy approach for the acquisition of computational resources to conduct NGS data analysis at a large scale.
The development of cloud-based bioinformatics platforms and services for large-scale NGS data analysis is expected to drive the market at a fast pace. BaseSpace, Bina, DNAnexus, LifeScope, GeneSifter and SevenBridges are some of the commercially available cloud-based NGS tools readily adopted by end-users to analyze sequencing information. The incorporation of NGS protocols has been specifically used for oncology precision medicine, especially for lung and breast cancers. Companies are also focused on developing low-cost genome sequencing solutions to enhance their businesses. For instance, in October 2021, Phase Genomics announced to launch a cost-effective platform for genome analysis.
Gather more insights about the market drivers, restrains and growth of the Global Next-Generation Sequencing Data Analysis Market
Similarly, various stakeholders in the industry are looking for companies that offer low-cost solutions. For instance, Gencoveraised USD 10 million to meet the demand for interpretable and accessible whole-genome sequencing. The company manages the cost by integrating low-pass whole-genome sequencing with a proprietary software-as-a-service computation.
The spontaneous spread of COVID-19 led to the increased emphasis on genome surveillance. Moreover, enhanced capabilities of genome surveillance can support the development of intelligent systems to track virus mutations and variants associated with respiratory conditions. In June 2021, the European Centre for Disease Prevention and Control announced the launch of EpiPulse, a European surveillance portal, for infectious diseases to gather, analyze and share sequencing data associated with infectious diseases.
Furthermore, the companies are engaged in the deployment of such surveillance platforms, which can provide a robust platform for sequencing and analysis of viruses. For instance, in March 2021, Applied DNA Sciences, Inc. announced the launch of the Linea Genomic Surveillance Mutation Panel for COVID-19 to consolidate the process associated with SARS-CoV-2 variant tracking and detection. Rising awareness and adoption of such genome surveillance platforms can play a powerful role in handling future health emergencies. In addition, the growth of such platforms is expected to create a lucrative growth opportunity for next-generation sequencing data analysis platforms in the coming years.
Browse through Grand View Research's Biotechnology Industry Research Reports.
• Synthetic Biology Market: The global synthetic biology market size was valued at USD 10,285.3 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 19.7% from 2022 to 2030. The increasing scope of synthetic biology applications for multiplexed diagnostics & cellular recording, as well as therapeutic genome editing, is anticipated to surge its demand during the study period.
• Cell Culture Media Market: The global cell culture media market size was valued at USD 3,616.8 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals.
Next-Generation Sequencing Data Analysis Market Segmentation
Grand View Research has segmented the global next-generation sequencing data analysis market on the basis of product, workflow, mode, read length, end-use, and region:
Next-generation Sequencing Data Analysis Product Outlook (Revenue, USD Million, 2017 - 2028)
• Services
• NGS Commercial Software
Next-generation Sequencing Data Analysis Workflow Outlook (Revenue, USD Million, 2017 - 2028)
• Primary
• Secondary
• Tertiary
Next-generation Sequencing Data Analysis Mode Outlook (Revenue, USD Million, 2017 - 2028)
• In-house
• Outsourced
Next-generation Sequencing Data Analysis Read Length Outlook (Revenue, USD Million, 2017 - 2028)
• Short Read
• Long Read
• Very Long Read
Next-generation Sequencing Data Analysis End-use Outlook (Revenue, USD Million, 2017 - 2028)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma& Biotech Entities
• Other Users
Next-generation Sequencing Data Analysis Regional Outlook (Revenue, USD Million, 2017 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East Africa (MEA)
Key Companies profiled:
Some prominent players in the Global Next-Generation Sequencing Data Analysis Market include
• Thermo Fisher Scientific, Inc.
• QIAGEN
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• PierianDx
• PrecigenBioinformatics Germany GmbH
• Partek Incorporated
• Eurofins Scientific
• Pacific Biosciences of California, Inc.
• DNASTAR, Inc.
• Congenica Ltd.
• Fabric Genomics, Inc.
• Genuity Science
• DNAnexus Inc.
• SciGenom Labs Pvt. Ltd.
• Golden Helix, Inc.
• Verily Life Science
Order a free sample PDF of the Next-Generation Sequencing Data Analysis Market Intelligence Study, published by Grand View Research.
Blood Testing Market Expected to Witness Massive Growth to 2028 [Business]
Blood Testing Industry Overview
The global blood testing market size was valued at USD 73.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.3% from 2021 to 2028. Growing medical spending by the government and regulatory bodies is expected to drive the market during the forecast period. Government and key organizations are constantly engaged in encouraging patients to undergo regular diagnostic examinations.
Multinational healthcare organizations aid in the discovery of novel techniques and promote awareness about the eradication and diagnosis of common as well as chronic disorders. Robust external funding to the clinical studies conducted for the development of novel innovative diagnostic tests is expected to boost the market. The introduction of constructive regulatory parameters that aim to promote the usage of POC testing is a high-impact rendering driver of the market.
Gather more insights about the market drivers, restrains and growth of the Global Blood Testing Market
Regulatory bodies such as FDA, Centers for Medicare and Medicaid Services (CMS), and Federal Trade Commission play an important role in the regulation of diagnostic tests. These bodies have undertaken initiatives to commercialize Clinical Laboratory Improvement Amendments (CLIA) compliant diagnostic tests that can aid in early disease detection. The introduction of CLIA in the U.S. is expected to boost usage rates of blood tests during the forecast period.
A continuous rise witnessed in the prevalence of chronic diseases along with high demand for rapid products for assessment of health conditions is expected to offer the market a significant momentum in the coming years. This is expected to provide lucrative opportunities to operational entities as blood testing is integral for the regular monitoring of diseases. Moreover, to provide swift services, clinics, hospitals, and other healthcare facilities are providing advanced tests. An exponential rise in the number of COVID-19 cases globally is boosting the demand for large-volume diagnostic testing.
Rapid diagnosis, effective treatment options, and future prevention plans are essential in the management of COVID-19. The current race for the development of test kits that are cost-effective and offer point-of-contact detection of coronavirus infection has led to rapid innovation in diagnostics. In July 2020, doctors in Washington examined blood for people affected with COVID-19 for identification of patients that are at great risk to encounter severe illness and to isolate the one who might need a ventilator during treatment.
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
• Point Of Care Diagnostics Market: The global point of care diagnostics market size was valued at USD 37.03 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.8% from 2022 to 2030. The market is set to gain momentum in the coming years on account of the increase in funding from multiple sources, the rising prevalence of target diseases, and the need to address the recent outbreak of coronavirus.
• In Vitro Diagnostics Market: The global in vitro diagnostic market size was valued at USD 111.67 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 0.2% from 2022 to 2030. The growth can be attributed to the increasing adoption of IVDowing to the rise in testing due to the pandemic.
Blood Testing Market Segmentation
Grand View Research has segmented the global blood testing market on the basis of test type and region:
Blood Testing Type Outlook (Revenue, USD Million, 2017 - 2028)
• Glucose
• A1C
• Direct LDL
• Lipid panel
• Prostate-specific antigen
• COVID-19
• BUN
• Vitamin D
• Thyroid-stimulating hormone
• Serum Nicotine / Cotinine
• High sensitivity CRP
• Testosterone
• ALT
• Cortisol
• Creatinine
• AST
• Other tests
Blood Testing Regional Outlook (Revenue, USD Million, 2017 - 2028)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)
Key Companies profiled:
Some prominent players in the Global Blood Testing Market include
• Abbott
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Quest Diagnostics
• Biomerica, Inc.
• Becton, Dickinson and Company
• Siemens Healthineers
• Danaher Corporation
• Trinity Biotech Plc
Order a free sample PDF of the Blood Testing Market Intelligence Study, published by Grand View Research.
